241 related articles for article (PubMed ID: 1639742)
1. Lack of association between fluoxetine and suicidality in bulimia nervosa.
Wheadon DE; Rampey AH; Thompson VL; Potvin JH; Masica DN; Beasley CM
J Clin Psychiatry; 1992 Jul; 53(7):235-41. PubMed ID: 1639742
[TBL] [Abstract][Full Text] [Related]
2. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
[TBL] [Abstract][Full Text] [Related]
5. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Tollefson GD; Rampey AH; Beasley CM; Enas GG; Potvin JH
J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412
[TBL] [Abstract][Full Text] [Related]
6. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley CM; Dornseif BE; Bosomworth JC; Sayler ME; Rampey AH; Heiligenstein JH; Thompson VL; Murphy DJ; Masica DN
BMJ; 1991 Sep; 303(6804):685-92. PubMed ID: 1833012
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group.
Arch Gen Psychiatry; 1992 Feb; 49(2):139-47. PubMed ID: 1550466
[TBL] [Abstract][Full Text] [Related]
9. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
[TBL] [Abstract][Full Text] [Related]
11. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
Tourian KA; Padmanabhan K; Groark J; Ninan PT
J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
14. Occurrence and course of suicidality during short-term treatment of late-life depression.
Szanto K; Mulsant BH; Houck P; Dew MA; Reynolds CF
Arch Gen Psychiatry; 2003 Jun; 60(6):610-7. PubMed ID: 12796224
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine: no association with suicidality in obsessive-compulsive disorder.
Beasley CM; Potvin JH; Masica DN; Wheadon DE; Dornseif BE; Genduso LA
J Affect Disord; 1992 Jan; 24(1):1-10. PubMed ID: 1545040
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
17. Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population?
Akiskal HS; Benazzi F
J Affect Disord; 2006 Aug; 94(1-3):105-10. PubMed ID: 16766043
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
Tollefson GD; Holman SL; Sayler ME; Potvin JH
J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
[TBL] [Abstract][Full Text] [Related]
19. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Tollefson GD; Fawcett J; Winokur G; Beasley CM; Potvin JH; Faries DE; Rampey AH; Sayler ME
Ann Clin Psychiatry; 1993 Dec; 5(4):209-24. PubMed ID: 8312978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
